In the present study, diagnostic methods for canine G M1 -gangliosidosis were examined by comparing a DNA mutation assay with an enzyme assay. Sixty-two Shiba dogs of a pedigree with G M1 -gangliosidosis were differentiated into 3 genotypes, i.e., normal, heterozygous, and homozygous affected dogs, using a DNA mutation assay, which consists of polymerase chain reaction amplification and the determination of restriction fragment length polymorphisms. The ␤-galactosidase activity in leukocytes, umbilical cords, and plasma was measured using 4-methylumbelliferyl ␤-D-galactoside and p-nitrophenyl ␤-D-galactoside as artificial substrates and compared among the 3 genotypes. The results showed that it was possible to identify homozygous dogs with the enzyme assay using leukocytes and umbilical cords. When using leukocytes, heterozygous carriers could be differentiated from normal dogs in many cases. However, the use of the DNA mutation assay is essential for a complete determination of heterozygous carriers because of the overlap in the distribution of enzyme activity between these 2 groups. When umbilical cords were used, heterozygous carriers could not be differentiated from normal dogs because of no significant difference in enzyme activity between these 2 groups. The ␤-galactosidase activity in plasma was not applicable to the diagnosis and genotyping of G M1 -gangliosidosis in Shiba dogs.
G M1 -gangliosidosis, a lysosomal storage disease that affects the brain and multiple systemic organs, is due to an autosomal recessively inherited deficiency of acid ␤-galactosidase activity. 7 The substrates of the enzyme, such as G M1 -ganglioside, and glycoconjugates with terminal ␤-galactose accumulate especially in the lysosomes of neurons, resulting in the manifestation of progressive neurological disorders. In principle, therefore, this disease is diagnosed on the basis of the absence of or a reduction in the activity of ␤-galactosidase or the presence of excessive amounts of G M1 -ganglioside in the central nervous system (or both). Furthermore, once a mutation is established for a family with ␤-galactosidase deficiency, rather simple procedures can be used for a rapid genetic diagnosis. The mutation is detected easily by restriction digestion, allele-specific oligonucleotide hybridization, or amplifi-cation refractory mutation system, in combination with polymerase chain reaction (PCR) amplification.
In domestic animals, naturally occurring G M1 -gangliosidosis has been reported in dogs, cats, calves, and sheep and is considered to be an authentic model of the human disease. 7 G M1 -gangliosidosis in Shiba dogs was identified originally in 2000. 12 Since then, a closed breeding colony has been maintained at the Graduate School of Veterinary Medicine, Hokkaido University (Sapporo, Hokkaido, Japan). 11 A homozygous recessive mutation causing G M1 -gangliosidosis in Shiba dogs has been identified as a deletion of C nucleotide 1647 in the putative coding region for canine ␤-galactosidase, 10 which can be detected by a PCR-restriction fragment length polymorphism (RFLP) method.
In the present study, a DNA mutation assay was compared with an enzyme assay using Shiba dogs which belong to a pedigree with G M1 -gangliosidosis, and the usefulness of these methods for the diagnosis of canine G M1 -gangliosidosis was discussed.
Materials and methods
Animals and sample collection. Sixty-two Shiba dogs of a pedigree with G M1 -gangliosidosis 11 were used in the present study. More than 2 ml of venous blood required for an enzyme assay was drawn from dogs aged more than 1 mo old using heparin (10-20 U/ml blood) as an anticoagulant and immediately incubated on ice. Plasma samples were pre-
Genotyping of Shiba dogs of a pedigree with G M1 -gangliosidosis by DNA mutation assay using a PCR and restriction endonuclease (Nci I). Lane M, marker; lanes 1 and 2, normal (clear) canine DNA without digestion (1) and digested with Nci I (2); lanes 3 and 4, heterozygous carrier DNA without digestion (3) and digested with Nci I (4); lanes 5 and 6, homozygous affected DNA without digestion (5) and digested with Nci I (6). pared from the heparinized blood by centrifugation at 1,250 ϫ g for 8 min. Leukocytes were isolated by a differential sedimentation procedure using 4% dextran a (MW 180,000-200,000) in physiological saline. 5 Umbilical cords were collected from 28 dogs at birth or within a few hours after birth. Venous blood was also collected from most of these dogs at 1 mo of age. Leukocyte pellets, plasma, and umbilical cords were frozen at Ϫ30 C before use. Genomic DNA was extracted from umbilical cords of 28 dogs, leukocytes of 33 dogs from which umbilical cords could not be collected, and muscle of 1 dog that died shortly after birth as a result of dystocia. All experimental procedures using experimental animals were performed in accordance with the guidelines regulating animal use at the Graduate School of Veterinary Medicine, Hokkaido University.
DNA mutation assay. The DNA mutation assay was performed according to a PCR-RFLP method reported previously. 10 Genomic DNA was isolated using a commercial kit. b The DNA was used as a template for PCR amplification of the target sequence in exon 15 of the canine ␤-galactosidase gene with forward (5Ј-AACACTGAGGATGCAGTA-CGCAGC-3Ј) and reverse (5Ј-TCCAGGAAACTGGA-TAAAGGTGTC-3Ј) primers in a 50 l reaction mixture containing 1ϫ PCR buffer, 0.2 mM deoxynucleoside 5Ј-triphosphate, 2.5 units of Taq polymerase, c and 25 pmol of the primers. Thirty-five cycles of amplification were carried out at a denaturing temperature of 94 C for 30 sec, an annealing temperature of 60 C for 30 sec, and an extension temperature of 72 C for 1 min. Extension during the last cycle was carried out for 5 min. The amplification product (8 l) was added together with 5 to 20 units of the restriction endonuclease Nci I d to a 10 l reaction mixture containing 1ϫ restriction endonuclease buffer and digested for 90 min at 37 C. Both the amplification and digested products were analyzed by 3% agarose gel e electrophoresis and ethidium bromide staining. A molecular weight standard f was used in the electrophoresis.
Measurement of acid ␤-galactosidase activity. Leukocytes and umbilical cords were homogenized in deionized water to yield 0.5 mg/ml protein. 2 The ␤-galactosidase activity in leukocyte and umbilical cord homogenates and plasma was measured spectrofluorometrically using 4-methylumbelliferyl ␤-D-galactoside g (4-MUGal) as a substrate. 6 The assay mixture contained 0.5 mM 4-MUGal and 25 g of protein or 50 l of plasma in 0.4 ml of 25 mM sodium citrate-phosphate buffer (pH 4.0). Incubation was for 1 hr at 37 C, and the liberated 4-methylumbelliferone was determined using a spectrofluorometer. h The activity of ␤-galactosidase was expressed as nmol/hr/mg protein or nmol/hr/ml plasma. The ␤-galactosidase activity was also measured spectrophotometrically using p-nitrophenyl ␤-D-galactoside g (PNPGal) as a substrate. 6 The assay mixture contained 5 mM PNPGal, and 50 g of protein or 100 l of plasma in 0.4 ml of 25 mM sodium citrate-phosphate buffer (pH 4.0). Incubation was for 1 hr at 37 C, and the amount of p-nitrophenol liberated was determined using a spectrophotometer. i The activity in plasma could not be measured using PNPGal because of the color of the plasma.
Statistical analysis. Statistical analysis was performed using 1-way factorial analysis of variance (ANOVA) with post hoc tests (Tukey method). Values of P Ͻ 0.05 were considered significant. These analyses were carried out on a computer using a statistical software package. j
Results
Genotype analysis. A restriction enzyme site for Nci I (C 1647 CCGG) in exon 15 is present in the normal canine ␤-galactosidase gene. This site is lost in the DNA of homozygous affected Shiba dogs by a deletion of C 1647 . This permits a genotypic analysis based on the different band fragments observed after PCR amplification and restriction enzyme digestion of the genomic DNA (Fig. 1) . A 185-bp DNA fragment was amplified by PCR and digested with Nci I, resulting in the formation of 2 fragments (104 and 80 bp) in normal dogs. In contrast, a 184-bp DNA fragment was amplified but could not be digested with Nci I in homozygous dogs. In heterozygous carriers, 3 fragments (184, 104, and 80 bp) formed after the restriction enzyme digestion. Using this DNA mutation assay, 62 dogs examined in the present study were differentiated into 3 genotypes: 23 normal dogs, 29 heterozygous carriers, and 10 homozygous dogs.
Acid ␤-galactosidase activity in leukocytes. Acid ␤galactosidase activity in leukocytes measured using 4-MUGal is shown in Fig. 2 . The activity in homozygous dogs (1.2 Ϯ 0.5 nmol/hour/mg protein, mean Ϯ standard deviation) was markedly low and was 1% of the activity in normal dogs (126.2 Ϯ 40.4 nmol/hour/ mg protein). The activity in heterozygous carriers (61.3 Ϯ 16.3 nmol/hour/mg protein) was 49% of the normal activity. There was an overlap in enzyme activity between normal and heterozygous dogs; however, there were significant differences (P Ͻ 0.001) among all the genotypes.
The activity levels measured using PNPGal were similar to those by 4-MUGal (Fig. 3 ). However, in homozygous dogs, the activity measured using PNPGal (15.8 Ϯ 8.1 nmol/hour/mg protein) was 10% of the normal activity (163.2 Ϯ 32.4 nmol/hour/mg protein) and was slightly higher than that measured by 4-MUGal. The activity in heterozygous dogs (88.2 Ϯ 17.3 nmol/hour/mg protein) was almost half (54%) of the normal activity. There was also an overlap in enzyme activity between normal and heterozygous dogs when measured using PNPGal. When the cutoff point was set up as 100 nmol/hour/ mg protein measured using 4-MUGal to identify heterozygous dogs, the sensitivity was 1.0, but the falsepositive value was 36.4% (8 of 22 normal dogs; specificity 0.636). When measured using PNPGal, with a cutoff point of 120 nmol/hour/mg protein, the sensitivity was 1.0 and the false-positive value was 9.5% (2 of 21 normal dogs; specificity 0.905). However, using these 2 cutoff points at the same time, only 1 normal dog was misjudged as a heterozygous carrier.
Acid ␤-galactosidase activity in umbilical cords. The activity in umbilical cords measured using 4-MU-Gal and PNPGal is shown in Figs. 4, 5 , respectively. In homozygous dogs, the levels of activity measured using both substrates were markedly low compared with those in normal and heterozygous dogs. However, there were no significant differences between normal and heterozygous dogs when measured using both substrates.
Acid ␤-galactosidase activity in plasma. The activity in plasma was significantly lower in homozygous and heterozygous dogs (P Ͻ 0.001 and P Ͻ 0.01, respectively) than in normal dogs (Fig. 6 ). However, there was an overlap in enzyme activity among all the genotypes showing no specificity for genotyping.
On the other hand, there was no effect of sex and age on the ␤-galactosidase activity in leukocytes, umbilical cords, and plasma from Shiba dogs.
Discussion
In humans, about 40 mutations causing ␤-galactosidase deficiency have been identified in the world population, 3 suggesting that the human ␤-galactosidase gene does not have hot spots in which mutations occur relatively easily. Therefore, biochemical diagnosis consisting of an analysis of storage compounds and enzyme assay must be applied to patients who do not belong to families with the known mutant alleles.
In dogs, the canine ␤-galactosidase gene may not have hot spots in which mutations occur relatively easily. Five canine breeds with G M1 -gangliosidosis have been reported, 12 and a homozygous recessive mutation in Portuguese Water Dogs has been identified, nucleotide G 179 → A in the putative coding region for the canine ␤-galactosidase gene, 8 in addition to the mutation in Shiba dogs. This point mutation is not responsible for the disease in English Springer Spaniels, on the basis of the negative result of a DNA mutation assay for detecting nucleotide G 179 → A. 8 In addition, Diagnosis of G M1 -gangliosidosis in Shiba dogs in mixed-breed Beagles and Alaskan Huskies, different mutations seem to cause the same disease because clinical features differ with breeds. 11 Therefore, the DNA mutation assay is only applicable to the diagnosis of a proper canine breed. However, the DNA mutation assay is a reliable method for the analysis of normal and mutant alleles, which simplifies genetic testing for carrier identification and breeding purposes. In the present study, a DNA mutation assay for the Shiba breed made carrier determination easy and reliable and enabled the accurate screening of carriers for breeding purposes.
For enzyme diagnosis of G M1 -gangliosidosis, leukocytes, fibroblasts, and solid tissues can usually be used as enzyme sources. 7 In the present study, ␤-galactosidase activity of leukocytes and umbilical cords was negligible in homozygous Shiba dogs when measured using both 4-MUGal and PNPGal, leading to the distinct determination of homozygous affected dogs. The enzyme assay using separated leukocytes seems to be the most useful for the diagnosis of G M1 -gangliosidosis because blood can be collected noninvasively and culture is not required, unlike for fibroblasts. In addition, 4-MUGal seems to have an advantage over PNPGal as an artificial substrate in that the activity measured using 4-MUGal was distinctively low and had a narrow deviation in homozygous dogs. For the diagnosis of newborn pups, umbilical cords were useful as sources of enzyme and genomic DNA because it is difficult to collect enough blood for the enzyme assay from newborn pups.
Carrier detection is important for a breeding purpose in the closed colony of this animal model and for genetic counseling to breeders who have produced homozygous dogs. In the present study, the mean value of leukocyte ␤-galactosidase activity in heterozygous carriers was almost half the normal value, and the difference was highly significant, which may be because of a half-level expression of normal messenger RNA and protein. Heterozygous carriers could be differentiated from normal dogs in many cases. However, clear genotyping of normal and heterozygous dogs could not be performed in some cases because of a slight overlap in the distribution of enzyme activity between these 2 groups. Therefore, the use of the DNA mutation assay is essential for the complete determination of heterozygous carriers.
In addition, leukocyte ␤-galactosidase activity can be increased to the normal range in heterozygous Portuguese Water Dogs that have been treated with corticosteroids for a long period leading to false-negative results. 9 These false-negative results are a result of the lymphocytopenia and an increased amount of older neutrophils in the peripheral blood. Although there were no Shiba dogs that were treated with corticosteroids in the present study, the effect of corticosteroids should be considered in the enzyme diagnosis of G M1gangliosidosis.
In a previous report, 1 the ␤-galactosidase activity in umbilical cords from newborn Portuguese Water Dog pups was used to identify the genotypes. It was described that the activity measured using 4-MUGal is 600-1,500 nmol/hour/mg protein in normal dogs, 150-300 nmol/hour/mg protein in heterozygous carriers, and 3-30 nmol/hour/mg protein in homozygous dogs. However, in the present study in Shiba dogs, the activity in umbilical cords was considerably lower than that in the Portuguese Water Dogs, and there was no significant difference between normal and heterozygous dogs, showing that the activity in umbilical cords cannot be used for the determination of carrier status in Shiba dogs with G M1 -gangliosidosis. Although the reason for this is not known, the activity in umbilical cords may differ greatly with breeds.
For the diagnosis of canine G M2 -gangliosidosis as well as the human disease, fluid samples such as serum and cerebrospinal fluid are useful as enzyme sources of ␤-hexosaminidase activity. 13 For the diagnosis of human G M1 -gangliosidosis, serum might potentially be useful and plasma gives more reliable enzymatic results. 4 However, in the present study, plasma was not suitable for the diagnosis of canine G M1 -gangliosidosis because there was no significant difference between heterozygous and homozygous dogs and there were overlaps in activity among all the genotypes.
In conclusion, the DNA mutation assay made it possible to diagnose G M1 -gangliosidosis early and precisely in Shiba dogs and to control the breeding colony genetically as an animal model. The enzyme assay should be applied to sporadic and solitary cases. In such cases, leukocytes were most suitable as the enzyme source and umbilical cords from newborn pups were also available for the detection of homozygous dogs. However, plasma was not suitable for the diagnosis of canine G M1 -gangliosidosis. As described above, the usefulness and limits of the DNA mutation assay and the enzyme assay were clarified.
